This company listing is no longer active
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
Liminal BioSciences 過去の業績
過去 基準チェック /06
Liminal BioSciences has been growing earnings at an average annual rate of 30.6%, while the Biotechs industry saw earnings growing at 27% annually. Revenues have been declining at an average rate of 72.7% per year.
主要情報
30.6%
収益成長率
72.8%
EPS成長率
| Biotechs 業界の成長 | -14.6% |
| 収益成長率 | -72.7% |
| 株主資本利益率 | -79.9% |
| ネット・マージン | -7,241.4% |
| 前回の決算情報 | 31 Dec 2022 |
最近の業績更新
Recent updates
収支内訳
Liminal BioSciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -29 | 18 | 0 |
| 30 Sep 22 | 0 | -31 | 20 | 0 |
| 30 Jun 22 | 1 | -35 | 25 | 0 |
| 31 Mar 22 | 0 | -42 | 29 | 0 |
| 31 Dec 21 | 1 | -44 | 32 | 0 |
| 30 Sep 21 | 1 | -48 | 34 | 0 |
| 30 Jun 21 | 1 | -49 | 32 | 0 |
| 31 Mar 21 | 1 | -35 | 30 | 0 |
| 31 Dec 20 | 1 | -48 | 33 | 0 |
| 30 Sep 20 | 1 | -75 | 35 | 0 |
| 30 Jun 20 | 2 | -94 | 38 | 0 |
| 31 Mar 20 | 3 | -232 | 49 | 0 |
| 31 Dec 19 | 1 | -150 | 38 | 0 |
| 30 Sep 19 | -8 | -299 | 44 | 0 |
| 30 Jun 19 | 3 | -298 | 40 | 0 |
| 31 Mar 19 | 23 | -194 | 29 | 0 |
| 31 Dec 18 | 25 | -197 | 29 | 0 |
| 30 Sep 18 | 43 | -131 | 50 | 0 |
| 30 Jun 18 | 55 | -118 | 52 | 0 |
| 31 Mar 18 | 39 | -115 | 53 | 0 |
| 31 Dec 17 | 22 | -112 | 50 | 0 |
| 30 Sep 17 | 37 | -109 | 32 | 0 |
| 30 Jun 17 | 16 | -119 | 31 | 0 |
| 31 Mar 17 | 16 | -112 | 28 | 0 |
| 31 Dec 16 | 16 | -101 | 26 | 0 |
| 30 Sep 16 | 26 | -74 | 22 | 0 |
| 30 Jun 16 | 28 | -58 | 19 | 0 |
質の高い収益: PJ2 is currently unprofitable.
利益率の向上: PJ2 is currently unprofitable.
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: PJ2 is unprofitable, but has reduced losses over the past 5 years at a rate of 30.6% per year.
成長の加速: Unable to compare PJ2's earnings growth over the past year to its 5-year average as it is currently unprofitable
収益対業界: PJ2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.2%).
株主資本利益率
高いROE: PJ2 has a negative Return on Equity (-79.86%), as it is currently unprofitable.